US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
US20030225150A1
(en)
*
|
1997-04-21 |
2003-12-04 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
|
AU3987299A
(en)
|
1998-05-12 |
1999-11-29 |
E-Ink Corporation |
Microencapsulated electrophoretic electrostatically-addressed media for drawing device applications
|
US20040053900A1
(en)
*
|
1998-12-23 |
2004-03-18 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
|
US20030203956A1
(en)
*
|
1998-12-23 |
2003-10-30 |
Masterrer Jaime L. |
Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US20020103141A1
(en)
*
|
1998-12-23 |
2002-08-01 |
Mckearn John P. |
Antiangiogenic combination therapy for the treatment of cancer
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US20030119895A1
(en)
*
|
1998-12-23 |
2003-06-26 |
Pharmacia Corporation |
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
|
US6458822B2
(en)
*
|
2000-03-13 |
2002-10-01 |
Pfizer Inc. |
2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
|
US6927216B2
(en)
*
|
2000-10-03 |
2005-08-09 |
Bristol-Myers Squibb Pharma Company |
Cyclic sulfonyl compounds as inhibitors of metalloproteases
|
PE20020801A1
(es)
|
2001-01-05 |
2002-09-06 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
SE0100902D0
(sv)
*
|
2001-03-15 |
2001-03-15 |
Astrazeneca Ab |
Compounds
|
SE0100903D0
(sv)
*
|
2001-03-15 |
2001-03-15 |
Astrazeneca Ab |
Compounds
|
SE0103710D0
(sv)
*
|
2001-11-07 |
2001-11-07 |
Astrazeneca Ab |
Compounds
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
AU2002349537A1
(en)
*
|
2001-11-29 |
2003-06-10 |
Nippon Organon K.K. |
Remedies for heart failure
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
US7091357B2
(en)
|
2001-12-26 |
2006-08-15 |
University Of Kentucky Research Foundation |
Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
|
CA2492035A1
(en)
*
|
2002-07-11 |
2004-01-15 |
Vicuron Pharmaceuticals, Inc. |
N-hydroxyamide derivatives possessing antibacterial activity
|
SE0202539D0
(sv)
*
|
2002-08-27 |
2002-08-27 |
Astrazeneca Ab |
Compounds
|
GB0221246D0
(en)
*
|
2002-09-13 |
2002-10-23 |
Astrazeneca Ab |
Compounds
|
RS20050430A
(en)
|
2002-12-19 |
2007-08-03 |
Pfizer Inc., |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
PT2251327E
(pt)
|
2003-11-19 |
2014-03-04 |
Array Biopharma Inc |
Inibidores heterocíclicos de mek
|
SE0401762D0
(sv)
*
|
2004-07-05 |
2004-07-05 |
Astrazeneca Ab |
Novel compounds
|
US7648992B2
(en)
|
2004-07-05 |
2010-01-19 |
Astrazeneca Ab |
Hydantoin derivatives for the treatment of obstructive airway diseases
|
CN101014365B
(zh)
|
2004-07-16 |
2011-04-13 |
辉瑞产品公司 |
使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
|
PL1786785T3
(pl)
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
|
SE0403085D0
(sv)
*
|
2004-12-17 |
2004-12-17 |
Astrazeneca Ab |
Novel componds
|
SE0403086D0
(sv)
*
|
2004-12-17 |
2004-12-17 |
Astrazeneca Ab |
Compounds
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
CN102304086B
(zh)
|
2005-05-18 |
2013-12-04 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
US7820664B2
(en)
|
2007-01-19 |
2010-10-26 |
Bayer Schering Pharma Ag |
Inhibitors of MEK
|
MX2008002073A
(es)
*
|
2005-08-12 |
2008-04-16 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios.
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
EP2012786B1
(de)
|
2006-04-18 |
2010-10-06 |
Ardea Biosciences, Inc. |
Pyridonsulfonamide und pyridonsulfamide als mek-hemmer
|
TW200831488A
(en)
*
|
2006-11-29 |
2008-08-01 |
Astrazeneca Ab |
Novel compounds
|
JP4782239B2
(ja)
|
2007-04-18 |
2011-09-28 |
ファイザー・プロダクツ・インク |
異常細胞増殖治療のためのスルホニルアミド誘導体
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
DK2222675T3
(da)
|
2007-12-19 |
2013-11-04 |
Genentech Inc |
5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
|
JP5710269B2
(ja)
|
2007-12-21 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
アザインドリジン類と使用方法
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US8895546B2
(en)
|
2009-03-27 |
2014-11-25 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
US20090258865A1
(en)
|
2008-03-28 |
2009-10-15 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
WO2009146555A1
(en)
*
|
2008-06-04 |
2009-12-10 |
Ambrilia Biopharma Inc. |
Hiv integrase inhibitors from pyridoxine
|
NZ594177A
(en)
|
2009-02-05 |
2014-02-28 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
EP2400985A2
(de)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(de)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2011014726A1
(en)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
ES2534358T3
(es)
|
2009-10-13 |
2015-04-21 |
Allomek Therapeutics, Llc |
Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades
|
SG10201500895XA
(en)
|
2009-11-05 |
2015-04-29 |
Rhizen Pharmaceuticals Sa |
Chromen-4-one Derivatives As Kinase Modulators
|
AU2011215900A1
(en)
|
2010-02-10 |
2012-07-26 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
MX343383B
(es)
|
2010-02-12 |
2016-11-03 |
Pfizer Inc * |
Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2582727B8
(de)
|
2010-06-16 |
2017-04-19 |
University of Pittsburgh- Of the Commonwealth System of Higher Education |
Antikörper zu endoplasmin und deren verwendung
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
US9353127B2
(en)
|
2011-02-15 |
2016-05-31 |
Immunogen, Inc. |
Methods of preparation of conjugates
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
EP3345624A1
(de)
|
2012-02-22 |
2018-07-11 |
The Regents Of The University Of Colorado |
Bouvardin-derivate und therapeutische verwendungen davon
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP3505534A1
(de)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
PL3584255T3
(pl)
|
2012-08-31 |
2022-05-16 |
Sutro Biopharma, Inc. |
Modyfikowane aminokwasy zawierające grupę azydkową
|
ES2644758T3
(es)
|
2012-10-16 |
2017-11-30 |
Tolero Pharmaceuticals, Inc. |
Moduladores de PKM2 y métodos para su uso
|
US9999680B2
(en)
|
2013-02-28 |
2018-06-19 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
ES2738493T3
(es)
|
2013-03-14 |
2020-01-23 |
Tolero Pharmaceuticals Inc |
Inhibidores de JAK2 y ALK2 y métodos para su uso
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3233829B1
(de)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidin und triazinderivate und deren verwendung als axl-inhibitoren
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Krasの縮合三環系インヒビターおよびその使用の方法
|
WO2016172214A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
KR102608921B1
(ko)
|
2015-05-18 |
2023-12-01 |
스미토모 파마 온콜로지, 인크. |
생체 이용률이 증가된 알보시딥 프로드러그
|
PL3265443T3
(pl)
*
|
2015-07-08 |
2020-06-29 |
Research & Business Foundation Sungkyunkwan University |
Pochodne karboksyamidowe pirolidyny oraz sposoby ich wytwarzania i stosowania
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
KR20180034538A
(ko)
|
2015-08-03 |
2018-04-04 |
톨레로 파마수티컬스, 인크. |
암의 치료를 위한 병행 요법
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356354A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
AU2016355433C1
(en)
|
2015-11-16 |
2021-12-16 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
EA201891304A1
(ru)
|
2015-12-03 |
2019-01-31 |
Агиос Фармасьютикалс, Инк. |
ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
CA3011455A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
ES2910787T3
(es)
|
2016-05-12 |
2022-05-13 |
Univ Michigan Regents |
Inhibidores de ASH1L y métodos de tratamiento con los mismos
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
JP2019534260A
(ja)
|
2016-10-07 |
2019-11-28 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤としての複素環式化合物およびその使用方法
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10132797B2
(en)
|
2016-12-19 |
2018-11-20 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
BR112019012976A2
(pt)
|
2016-12-22 |
2019-12-31 |
Amgen Inc |
inibidores de kras g12c e métodos de uso dos mesmos
|
AU2018213718B2
(en)
|
2017-01-26 |
2022-08-25 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液***恶性肿瘤和尤因肉瘤的方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
CN107434778A
(zh)
*
|
2017-05-23 |
2017-12-05 |
重庆文理学院 |
一种4‑羟基‑2h‑吡咯‑2‑酮衍生物的制备方法
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
EP3684814A1
(de)
|
2017-09-18 |
2020-07-29 |
Sutro Biopharma, Inc. |
Anti-folat-rezeptor-alpha-antikörperkonjugate und ihre verwendung
|
TW201920170A
(zh)
|
2017-09-20 |
2019-06-01 |
美商庫拉腫瘤技術股份有限公司 |
經取代之menin-mll 抑制劑及使用方法
|
CN111655257A
(zh)
|
2017-11-10 |
2020-09-11 |
密歇根大学董事会 |
Ash1l抑制剂及用其进行治疗的方法
|
TWI811767B
(zh)
|
2018-02-28 |
2023-08-11 |
韓商畢利吉生物科技股份有限公司 |
脂化肽的水溶性鹽以及製備與使用其的方法
|
US11013741B1
(en)
|
2018-04-05 |
2021-05-25 |
Sumitomo Dainippon Pharma Oncology, Inc. |
AXL kinase inhibitors and use of the same
|
AU2019262589B2
(en)
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3788053A1
(de)
|
2018-05-04 |
2021-03-10 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
JP7361720B2
(ja)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
がんの治療のためのkras g12c阻害剤
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
US11319302B2
(en)
|
2018-06-07 |
2022-05-03 |
The Regents Of The University Of Michigan |
PRC1 inhibitors and methods of treatment therewith
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
CA3103995A1
(en)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MA55136A
(fr)
|
2018-11-19 |
2022-02-23 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3890749A4
(de)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9-inhibitoren und polymorphe davon zur verwendung als mittel zur behandlung von krebs
|
JOP20210154B1
(ar)
|
2018-12-20 |
2023-09-17 |
Amgen Inc |
مثبطات kif18a
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
EP3941463A1
(de)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Zusammensetzungen mit pkm2-modulatoren und behandlungsverfahren damit
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
CR20210665A
(es)
|
2019-05-21 |
2022-01-25 |
Amgen Inc |
Formas en estado sólido
|
WO2021003417A1
(en)
|
2019-07-03 |
2021-01-07 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
US20220281843A1
(en)
|
2019-08-02 |
2022-09-08 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022542319A
(ja)
|
2019-08-02 |
2022-09-30 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
CN114391012A
(zh)
|
2019-08-02 |
2022-04-22 |
美国安进公司 |
作为kif18a抑制剂的吡啶衍生物
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
EP4048671A1
(de)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidinderivate als kras-sg12c- und kras-g12d-inhibitoren zur behandlung von krebs
|
AU2020372881A1
(en)
|
2019-10-28 |
2022-06-09 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of KRAS G12C mutant
|
CN115551500A
(zh)
|
2019-10-31 |
2022-12-30 |
大鹏药品工业株式会社 |
4-氨基丁-2-烯酰胺衍生物及其盐
|
AU2020379731A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
WO2021091982A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN116425742A
(zh)
|
2019-11-08 |
2023-07-14 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
WO2021097207A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
BR112022009390A2
(pt)
|
2019-11-14 |
2022-08-09 |
Amgen Inc |
Síntese melhorada de composto inibidor de kras g12c
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
EP4087611A1
(de)
|
2020-01-07 |
2022-11-16 |
Revolution Medicines, Inc. |
Shp2-inhibitordosierung und verfahren zum behandeln von krebs
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
EP4114852A1
(de)
|
2020-03-03 |
2023-01-11 |
Sutro Biopharma, Inc. |
Antikörper mit stellenspezifischen glutamin-tags, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung
|
EP4139299A1
(de)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras-g12d-proteinhemmer
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
EP4168002A1
(de)
|
2020-06-18 |
2023-04-26 |
Revolution Medicines, Inc. |
Verfahren zur verzögerung, prävention und behandlung von erworbener resistenz gegen ras-inhibitoren
|
JP2023533982A
(ja)
|
2020-07-10 |
2023-08-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Gas41阻害剤及びその使用方法
|
TW202216151A
(zh)
|
2020-07-15 |
2022-05-01 |
日商大鵬藥品工業股份有限公司 |
含有使用於腫瘤之治療之嘧啶化合物之組合
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
RU2769521C1
(ru)
*
|
2021-02-17 |
2022-04-01 |
Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук |
(2S,4S)-4-Амино-N-(4-фторфенил)пироглутаминовая кислота, обладающая церебропротекторным, ноотропным и антитромботическим действием
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
US20230106174A1
(en)
|
2021-05-05 |
2023-04-06 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
WO2022250170A1
(en)
|
2021-05-28 |
2022-12-01 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
CN114306241B
(zh)
*
|
2021-12-29 |
2022-10-04 |
中山大学附属第一医院 |
一种微环境t细胞功能调控的纳米递送***及其制备方法和应用
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|